Harel contributed to drug discovery technology developer Eikon Therapeutics' $518m series B round while a host of corporates are set to exit data management software provider Trifacta in a $400m acquisition.
Funding
Eikon Therapeutics, a US-based developer of microscopy drug discovery technology, raised approximately $518m yesterday in a series B round featuring insurance firm Harel Insurance. It was joined by T Rowe Price, Canada Pension Plan Investment Board, EcoR1 Capital, UC Investments, Abu Dhabi Investment Authority’s ADIA subsidiary, StepStone Group, Soros Capital, Schroders Capital, General Catalyst, E15 VC, Hartford HealthCare Endowment, AME Cloud Ventures and existing backers The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital and Horizons Ventures.
Electronics producer…
